Agenus director granted 100,000 stock options

AGENUS INC director Brian Corvese received a compensatory grant of 100,000 stock options on 2026-08-05.

Rhea-AI Filing Summary

AGENUS INC director Brian Corvese received a compensatory grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.78 per share, expire on 2036-08-05, and were awarded under the company’s 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Corvese Brian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 100,000 contracts (Direct)

Footnotes (1)

1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

Key Figures

Stock options granted: 100,000 options Exercise price: $7.78 per share Expiration date: 2036-08-05 +2 more

5 metrics

Stock options granted 100,000 options Grant to director Brian Corvese on 2026-08-05

Exercise price $7.78 per share Exercise price of the granted stock options

Expiration date 2036-08-05 Option term under the 2019 Amended and Restated Equity Incentive Plan

Shares underlying options 100,000 shares Common stock underlying the stock option grant

Vesting period 3 years One-third after one year, remaining two-thirds in two annual installments

Key Terms

Stock Option, Equity Incentive Plan, vesting

3 terms

Stock Option financial

"The security reported is a Stock Option exercisable for common stock."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Equity Incentive Plan financial

"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"Options vest over three years, with one-third vesting on the first anniversary."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AGEN (AGENUS INC) report for Brian Corvese?

AGEN reported that director Brian Corvese received a grant of 100,000 stock options on 2026-08-05 as part of his compensation, rather than a market purchase or sale of existing shares.

What are the key terms of Brian Corvese’s new AGEN stock options?

The grant consists of 100,000 stock options with an exercise price of $7.78 per share, expiring on 2036-08-05. The options relate to AGENUS INC common stock and are held directly.

How do Brian Corvese’s AGEN stock options vest over time?

The options vest over three years. One-third vests on the first anniversary of the grant date, and the remaining two-thirds vest in two equal annual installments thereafter, subject to the plan’s terms.

Under which equity plan were the AGEN options granted to Brian Corvese?

The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, which governs equity-based compensation such as stock option grants to directors and other eligible participants.

How many AGEN stock options does Brian Corvese hold after this grant?

Following this transaction, Brian Corvese holds 100,000 stock options reported in this filing. These options give him the right to buy an equivalent number of AGENUS INC common shares at the specified exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corvese Brian

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.78	08/05/2026		A		100,000		(1)	08/05/2036	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

	/s/Melissa Orilall, as Attorney-in-Fact for Brian Corvese	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)